Global prevalence of pre-existing antibodies against human adenoviruses, surveyed from 1962-2021

Hui Luo,Qian Zhou,Jinqi Feng,Yi Wu,Huangliang Chen,Meihan Mao,Rui Qi

DOI: https://doi.org/10.1159/000538233

2024-03-08

Intervirology

Abstract:Background: Human Adenoviruses (HAdVs) are extensively used as vectors for vaccines development and cancer therapy. People who already have antibodies against HAdVs, on the other hand, would have an impact on the preventative or therapeutic effect. This review focuses primarily on the prevalence of pre-existing antibodies against HAdVs in distinct geographical populations. Summary: After screening, 64 studies from 31 countries between 1962 and 2021 were selected, totaling 39,427 samples. The total prevalence of pre-existing antibodies to HAdVs varied by country or location, ranging from 2.00% to 95.70%. Southeast Asia had the highest prevalence (54.57%) while Europe had the lowest (18.17%). The prevalence in practically all developing nations was higher than in developed nations. Adults have a greater frequency than children and newborns in most nations. The primary HAdV antibody types varied by country. Adults in China, the United States, the United Kingdom, and Belgium had the lowest prevalence of pre-existing antibodies against HAdV55, HAdV37, HAdV8, and HAdV36, respectively. Children in the United States, China, the United Kingdom, and Japan had the lowest rates of HAdV48, HAdV11, HAdV8, and HAdV40. The frequency of antibodies differed significantly between military and civilian groups. Key Messages: Pre-existing antibodies against various types of HAdVs differed greatly throughout worldwide populations. Future development of HAdV-vector vaccines and medicines should focus on pre-existing antibodies in target groups rather than a "one-size-fits-all" strategy. It might be advantageous in selecting HAdV vectors for studying the prevalence of pre-existing antibodies against HAdVs in different locations and people throughout the world.

virology